GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (NEOE:BMND) » Definitions » EV-to-FCF

Biomind Labs (NEOE:BMND) EV-to-FCF : -45.54 (As of Jul. 23, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biomind Labs's Enterprise Value is C$28.32 Mil. Biomind Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.62 Mil. Therefore, Biomind Labs's EV-to-FCF for today is -45.54.

The historical rank and industry rank for Biomind Labs's EV-to-FCF or its related term are showing as below:

NEOE:BMND' s EV-to-FCF Range Over the Past 10 Years
Min: -45.54   Med: 0   Max: 0
Current: -45.54

NEOE:BMND's EV-to-FCF is ranked worse than
100% of 380 companies
in the Biotechnology industry
Industry Median: 9.67 vs NEOE:BMND: -45.54

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-07-23), Biomind Labs's stock price is C$0.35. Biomind Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.020. Therefore, Biomind Labs's PE Ratio (TTM) for today is At Loss.


Biomind Labs EV-to-FCF Historical Data

The historical data trend for Biomind Labs's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs EV-to-FCF Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
-36.42 -23.02 -11.84

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.48 -11.84 -39.17 -31.14 -65.47

Competitive Comparison of Biomind Labs's EV-to-FCF

For the Biotechnology subindustry, Biomind Labs's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomind Labs's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biomind Labs's EV-to-FCF falls into.


;
;

Biomind Labs EV-to-FCF Calculation

Biomind Labs's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=28.323/-0.622
=-45.54

Biomind Labs's current Enterprise Value is C$28.32 Mil.
Biomind Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomind Labs  (NEOE:BMND) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Biomind Labs's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.35/-0.020
=At Loss

Biomind Labs's share price for today is C$0.35.
Biomind Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.020.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biomind Labs EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Biomind Labs's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs Headlines

No Headlines